MX2021015947A - Métodos para tratar trastornos neurodegenerativos solicitudes relacionadas. - Google Patents

Métodos para tratar trastornos neurodegenerativos solicitudes relacionadas.

Info

Publication number
MX2021015947A
MX2021015947A MX2021015947A MX2021015947A MX2021015947A MX 2021015947 A MX2021015947 A MX 2021015947A MX 2021015947 A MX2021015947 A MX 2021015947A MX 2021015947 A MX2021015947 A MX 2021015947A MX 2021015947 A MX2021015947 A MX 2021015947A
Authority
MX
Mexico
Prior art keywords
methods
neurodegenerative disorders
treating neurodegenerative
treating
subjects
Prior art date
Application number
MX2021015947A
Other languages
English (en)
Inventor
Susan Abushakra
Martin Tolar
John Hey
Aidan Power
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of MX2021015947A publication Critical patent/MX2021015947A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)

Abstract

En la presente se proporcionan métodos para usar el volumen del hipocampo y/o el grosor cortical en sujetos humanos como predictores de la enfermedad de Alzheimer (EA) y para tratar sujetos que se ha determinado que están en riesgo de padecer EA o una disminución del deterioro cognitivo.
MX2021015947A 2019-06-17 2020-06-16 Métodos para tratar trastornos neurodegenerativos solicitudes relacionadas. MX2021015947A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962862400P 2019-06-17 2019-06-17
US201962944179P 2019-12-05 2019-12-05
PCT/US2020/037878 WO2020257159A1 (en) 2019-06-17 2020-06-16 Methods for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
MX2021015947A true MX2021015947A (es) 2022-04-18

Family

ID=71409566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015947A MX2021015947A (es) 2019-06-17 2020-06-16 Métodos para tratar trastornos neurodegenerativos solicitudes relacionadas.

Country Status (11)

Country Link
US (1) US20230024950A1 (es)
EP (1) EP3983563A1 (es)
JP (1) JP2022536803A (es)
KR (1) KR20220024434A (es)
CN (1) CN114269949A (es)
AU (1) AU2020294625A1 (es)
BR (1) BR112021025504A2 (es)
CA (1) CA3144008A1 (es)
IL (1) IL289018A (es)
MX (1) MX2021015947A (es)
WO (1) WO2020257159A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116662835A (zh) 2022-02-18 2023-08-29 医疗研究开发有限公司 分层方法以及分层装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2960625T3 (es) 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
ES2952727T3 (es) * 2015-09-10 2023-11-03 Alzheon Inc Tratamiento de la enfermedad de Alzheimer en una población de pacientes particular
WO2018157014A1 (en) * 2017-02-24 2018-08-30 Duke University Metabolic biomarkers for the identification and characterization of alzheimer's disease

Also Published As

Publication number Publication date
WO2020257159A1 (en) 2020-12-24
US20230024950A1 (en) 2023-01-26
EP3983563A1 (en) 2022-04-20
AU2020294625A1 (en) 2022-01-20
BR112021025504A2 (pt) 2022-04-26
JP2022536803A (ja) 2022-08-18
CN114269949A (zh) 2022-04-01
CA3144008A1 (en) 2020-12-24
KR20220024434A (ko) 2022-03-03
IL289018A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
Mertens et al. Cochlear implantation as a long-term treatment for ipsilateral incapacitating tinnitus in subjects with unilateral hearing loss up to 10 years
AU2019262220A8 (en) Methods of diagnosing and treating based on site-specific tau phosphorylation
MY159562A (en) Adipose tissue derived stromal cells for the treatment of neurological disorders
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
MY179105A (en) Methods of treating alzheimer&#39;s disease
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
NZ607195A (en) Methods for treating and/or reversing neurodegenerative diseases and/or disorders
EA201290764A1 (ru) Способы и композиции для улучшения когнитивной функции
MX347591B (es) Agentes de enlace amiloides.
IL291130A (en) Biomarkers and treatments in Alzheimer&#39;s disease and mild cognitive impairment
IL280315A (en) Methods for treating and preventing Alzheimer&#39;s disease
SG11201809512TA (en) Synapse formation agent
EP3740761A4 (en) ACCOMPANYING DIAGNOSTICS FOR NSAIDS AND DONEPEZIL FOR THE TREATMENT OF SPECIFIC SUBPOPULATIONS OF PATIENTS WITH ALZHEIMER&#39;S MORBUS
MX2021015947A (es) Métodos para tratar trastornos neurodegenerativos solicitudes relacionadas.
GB202015788D0 (en) Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
MX2022010674A (es) Población de linfocitos y métodos para producirla.
MX2021002936A (es) Uso de recambio plasmatico de bajo volumen para el tratamiento de la enfermedad de alzheimer en etapas temprana y moderada.
EA202290037A1 (ru) Способы лечения нейродегенеративных нарушений
MX2023010625A (es) Anticuerpos anti-beta amiloide y usos de estos.
IL288678A (en) Treatment of heart failure in human subjects
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
MX2022002629A (es) Rebamipida para usarse en la prevencion y tratamiento de la enfermedad de crohn.
MX2021013360A (es) Rebamipida para usarse en la prevencion y/o tratamiento de sinucleinopatias.